[Education] Adult Sarcomas: Top 10 Clinical Pearls

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

 

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

 

In this episode of HOPA Now, Dr. Christy Harris addresses the top ten clinical pearls regarding adult sarcomas, including an overview of the approval, dosage, and warnings of various drug treatments including doxorubicin, avipritinib, pexidartinib, and tazemetostat. She concludes with recommendations for regimens and collaborations that will produce optimal results for all clinical trials and patients.

 

In this episode, you will learn:

 

Adult Sarcomas: Top 10 Clinical Pearls

• An overview of the origin and main categories of sarcoma cancers
• Doxorubicin as the standard treatment option for sarcoma cancers
• Recommendations for dosage and monitoring of ifosfamide-induced encephalopathy
• Targets as an area of possible therapeutic benefit in various sarcomas
• An overview of the newly recognized gastrointestinal stromal tumor (GIST)
• The role, approval, and warnings associated with the new drugs avipritinib and pexidartinib
• Understanding epithelioid sarcomas next new therapy — tazemetostat
• Oral targeted therapies that best demonstrate advancement in the cancer arena

 

Mentioned in This Episode:

HOPA

 

Quotes:

 

“Sarcomas are a large, heterogeneous group of cancers that arise from connective tissues such as bone, skeletal and smooth muscle, adipose tissue and cartilage.” — Dr. Christy Harris

 

“Doxorubicin remains the standard for treatment for most sarcomas. Other agents may be added to it, but doxorubicin remains the workhorse of the sarcoma world.” — Dr. Christy Harris

 

“Targets have been identified as possible areas of therapeutic benefit for a number of sarcomas.” — Dr. Christy Harris

 

“Sarcomas are an uncommon tumor for most clinicians to see, but there is an increasing number of oral targeted therapies for individual tumors that demonstrate some advancement in the cancer arena.” — Dr. Christy Harris